Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study

BACKGROUND: Bevacizumab (BEV), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, enhances the antitumor effectiveness of paclitaxel (PTX)-based chemotherapy in many metastatic cancers. A recent study in mice showed that VEGF receptor inhibitors can interfere with the ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Ayumu, Maeda, Osamu, Mizutani, Takefumi, Nakano, Yasuyuki, Tsunoda, Nobuyuki, Kikumori, Toyone, Goto, Hidemi, Ando, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167416/
https://www.ncbi.nlm.nih.gov/pubmed/27992556
http://dx.doi.org/10.1371/journal.pone.0168707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167416/
https://www.ncbi.nlm.nih.gov/pubmed/27992556
http://dx.doi.org/10.1371/journal.pone.0168707

Ejemplares similares